VISTAGEN THERAPEUTICS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount
VISTAGEN THERAPEUTICS, INC. (VTGN) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount of $0 for the 12-month period ending 2026-03-31, per its 10-K filed 2026-06-15.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-06-15
- VISTAGEN THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for the quarter ending 2020-06-30 was $29.40K.
- VISTAGEN THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2026 was $0.00, a 100.00% decline from fiscal 2025.
- VISTAGEN THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2025 was $309.00K.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 3 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month |
|---|---|---|
| 2026-03-31 | $0.00 10-K · filed 2026-06-15 | |
| 2025-03-31 | $309.00K 10-K · filed 2026-06-15 | |
| 2020-06-30 | $29.40K 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |